Academic Journal
IS7. lung cancercircled1
| العنوان: | IS7. lung cancercircled1 |
|---|---|
| المؤلفون: | Yang, J. C. -H., Wu, Y.-L., Au, J. S.-K., Yuankai, S., Thongprasert, S., Srinivasan, S., Tsai, C.-M., Khoa, M. T., Heeroma, K., Itoh, Y., Cornelio, G., Yang, P.-C., O'Connell, J., Bottomley, A., Ramalingam, S. S, Boyer, M. J., Park, K., Blackhall, F., Mundayat, R., Lee, S.-Y., Campbell, A., Sun, J.-M., Kim, S.-W., Ahn, M.-J., Ahn, J. S., Lee, D. H., Ahn, Y. C., Pyo, H., Choi, E. K., Song, S. Y., Lee, S.-H., Suh, C., Lee, J. S., Hida, T., Kubota, K., Ishikura, S., Shibata, T., Nishio, M., Kawahara, M., Yokoyama, A., Imamura, F., Takeda, K., Negoro, S., Okamoto, H., Yamamoto, N., Shinkai, T., Saijo, N., Tamura, T., Kaneda, H., Kotani, Y., Satouchi, M., Ando, M., Ichinose, Y., Ohe, Y., Kudoh, S., Minato, K., Inoue, A., Maemondo, M., Sugawara, S., Harada, T., Minegishi, Y., Usui, K., Morikawa, N., Mori, Y., Ishimoto, O., Matsubara, N., Sakakibara, T., Watanabe, K., Gemma, A., Nukiwa, T., Shukuya, T., Atagi, S., Sawa, T., Mori, K., Kumagai, T., Sekiguchi, R., Enatsu, S., Nakagawa, K., Urata, Y., Okamoto, I., Hattori, Y., Okuno, K., Shimada, T., Takeda, M., Kurata, T., Miyazaki, M, Terashima, M., Tanaka, K., Morita, S, Murakami, H., Seto, T., Kiura, K., Kim, D.-W., Ahn, M.-J, Shi, Y., De Pas, T. M., Yang, P.-C, Riely, G. J., Crinò, L., Evans, T. L., Liu, X., Han, J.-Y., Salgia, R., Lanzalone, S., Polli, A., Iyer, S., Shaw, A. T., Scagliotti, G. V., Ou, S.-H. I., Gettinger, S. N., Besse, B., Thomas, M., Wilner, K., Bartlett, C. H., Gandara, D. R., Bang, Y.-J., Ou, S., Camidge, D. R., Clark, J. W., Tye, L., Stephenson, P., Varella-Garcia, M., Iafrate, A. J., Scagliotti, G., Spigel, D., Kim, J. H., Hsia, T.-C., Li, R. K., Tiangco, B., Yau, S., Lim, W.-T., Yao, B., Hei, Y.-j., Kris, M. G., Mok, T., Martins, R. G., Goldberg, Z., Zhang, H., Taylor, I., Letrent, S. P., Jänne, P. A., Ichihara, E., Hisamoto, A., Harita, S., Segawa, Y., Kamei, H., Shibayama, T., Gemba, K., Hotta, K., Matsuo, K., Aoe, K., Takigawa, N., Tabata, M., Tanimoto, M., Niho, S., Sakai, H., Isobe, H., Kunitoh, H., Takiguchi, Y., Kobayashi, K., Nakamura, Y., Katakami, N., Takeuchi, M. |
| بيانات النشر: | Oxford University Press |
| سنة النشر: | 2012 |
| المجموعة: | HighWire Press (Stanford University) |
| مصطلحات موضوعية: | abstracts |
| الوصف: | Advanced non-small-cell lung cancer (NSCLC) patients may benefit from several chemotherapeutic or targeted agents. However, patients respond differently to the same treatment in terms of anticancer efficacy or side-effects. As the choices for patients increase over the time along with advances in clinical research, selecting the right agents that provide patients with best chance of anticancer activity and lowest possibility of toxicity is the main theme in future research and clinical practice. Gene expressions in tumor cells may be good biomarkers for selecting treatment. Somatic gene expression may indirectly affect tumor gene and also determine the toxicity to various treatment. Several biomarkers were found to be correlated well with efficacy of drug treatment. For example, mutations in the exon 21 (L858R) and deletion in exon 19 of epidermal growth factor receptor (EGFR) were found to be correlated well with responsiveness to EGFR tyrosine kinase inhibitors such as gefitinib or erlotinib. The discovery of EML4-ALK or a ROS1 translocation predicted good response to ALK inhibitor crizotinib. The above-mentioned predictive factors for drug responsiveness were also prognostic factors for survival time. For example, activating mutation of EGFR may be a good prognostic factor for advanced NSCLC patients in addition to its role as a good predictive factor for EGFR-TKI treatment response. The results of Iressa Pan-Asian Survival Study (IPASS) have shown that patients whose tumor samples have tested positive for EGFR mutations may receive gefitinib as first-line treatment. The progression-free survival for those patients receiving gefitinib was longer than those receiving paclitaxel and carboplatin. The response rate of gefitinib for patients with EGFR mutation was 70% and that of wild-type patients was only 1%. In the updated final overall survival analysis, IPASS showed that overall survival was similar, with no significant difference, between gefitinib and carboplatin/paclitaxel in between treatment arms for OS ... |
| نوع الوثيقة: | text |
| وصف الملف: | text/html |
| اللغة: | English |
| Relation: | http://annonc.oxfordjournals.org/cgi/content/short/23/suppl_11/xi29; http://dx.doi.org/10.1093/annonc/mds554 |
| DOI: | 10.1093/annonc/mds554 |
| الاتاحة: | http://annonc.oxfordjournals.org/cgi/content/short/23/suppl_11/xi29 https://doi.org/10.1093/annonc/mds554 |
| Rights: | Copyright (C) 2012, European Society for Medical Oncology |
| رقم الانضمام: | edsbas.2F034360 |
| قاعدة البيانات: | BASE |
| DOI: | 10.1093/annonc/mds554 |
|---|